At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GPCR STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD
Trading 10-09 10:06:09 EDT
25.79
+0.12
+0.45%
High25.91Low25.44Vol33.65K
Open25.73D1 Closing25.67Amplitude1.83%
Mkt Cap1.84BTradable Cap1.43BTotal Shares71.31M
T/O863.79KT/O Rate0.06%Tradable Shares55.46M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Structure Therapeutics on Track for Lowest Close Since September 2025
Dow Jones  ·  00:19
Structure Therapeutics on Track for Lowest Close Since September 2025
23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?
Options & Short Sell  ·  10-01
23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?
Structure Therapeutics CMO Blas Coll Crespo Disposes of USD 124,008 Common Shares
Reuters  ·  09-23
Structure Therapeutics CMO Blas Coll Crespo Disposes of USD 124,008 Common Shares
Lilly: Foundayo Has Captured Over 30% Of New Patient Share In The U.S. Oral Weight-Loss Drug Market
Bellwether Stocks Movement  ·  09-15
Lilly: Foundayo Has Captured Over 30% Of New Patient Share In The U.S. Oral Weight-Loss Drug Market
AstraZeneca's Breast Cancer Drug Etcamah Hits A Phase 3 Setback, Clouding Billions In Potential Sales
Options & Short Sell  ·  09-14
AstraZeneca's Breast Cancer Drug Etcamah Hits A Phase 3 Setback, Clouding Billions In Potential Sales
GE HealthCare Plans $1 Billion Sofie Deal To Tap Fast-Growing Radiopharmaceuticals Market
Options & Short Sell  ·  09-14
GE HealthCare Plans $1 Billion Sofie Deal To Tap Fast-Growing Radiopharmaceuticals Market
Structure weakness ‘disconnected’ from underlying data, says Jefferies
TIPRANKS  ·  09-09
Structure weakness ‘disconnected’ from underlying data, says Jefferies
Structure Falls as Investors Await More Obesity Trial Data, Says Jefferies
Reuters  ·  09-09
Structure Falls as Investors Await More Obesity Trial Data, Says Jefferies
Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TIPRANKS  ·  09-09
Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Structure obesity portfolio updates ‘encouraging,’ says Clear Street
TIPRANKS  ·  09-09
Structure obesity portfolio updates ‘encouraging,’ says Clear Street
Structure Therapeutics reports ACCG-2671, aleniglipron trial results
TIPRANKS  ·  09-08
Structure Therapeutics reports ACCG-2671, aleniglipron trial results
Structure Therapeutics Releases Amylin and GLP-1 Program Presentation
Reuters  ·  09-08
Structure Therapeutics Releases Amylin and GLP-1 Program Presentation
Structure Therapeutics Reports Phase 1/2a Data Showing 3.3% Weight Loss for Oral Amylin Agonist ACCG-2671
Reuters  ·  09-08
Structure Therapeutics Reports Phase 1/2a Data Showing 3.3% Weight Loss for Oral Amylin Agonist ACCG-2671
Structure Therapeutics - Aleniglipron Demonstrates up to 16.2% Body Weight Reduction at 72 Weeks in Access Ole Trial
THOMSON REUTERS  ·  09-08
Structure Therapeutics - Aleniglipron Demonstrates up to 16.2% Body Weight Reduction at 72 Weeks in Access Ole Trial
Structure Therapeutics - Accg-2671 Demonstrates About 6-Day Half-Life, no Serious Adverse Events, 3.3% Body Weight Loss in Phase 1/2a Sad Trial
THOMSON REUTERS  ·  09-08
Structure Therapeutics - Accg-2671 Demonstrates About 6-Day Half-Life, no Serious Adverse Events, 3.3% Body Weight Loss in Phase 1/2a Sad Trial
Structure Therapeutics - Additional Clinical Data for Aleniglipron Expected in Q4 2026
THOMSON REUTERS  ·  09-08
Structure Therapeutics - Additional Clinical Data for Aleniglipron Expected in Q4 2026
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and Glp-1 Programs for Chronic Weight Management
THOMSON REUTERS  ·  09-08
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and Glp-1 Programs for Chronic Weight Management
Structure Therapeutics - First Participants Dosed with Accg-2671 in 12-Week Mad Phase 1/2a Trial; Topline Data Expected 1H 2027
THOMSON REUTERS  ·  09-08
Structure Therapeutics - First Participants Dosed with Accg-2671 in 12-Week Mad Phase 1/2a Trial; Topline Data Expected 1H 2027
Structure Therapeutics Management Joins Three September Healthcare Investor Conferences
Reuters  ·  09-03
Structure Therapeutics Management Joins Three September Healthcare Investor Conferences
Structure Therapeutics CSO Lin Xichen Reports Disposal of Common Shares Worth $275,830.34
Reuters  ·  09-03
Structure Therapeutics CSO Lin Xichen Reports Disposal of Common Shares Worth $275,830.34

Introduction

Company Name.
STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.
Issue price:
--